![PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) | A Treatment for HER2-Positive Breast Cancer PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) | A Treatment for HER2-Positive Breast Cancer](https://www.phesgo.com/content/dam/gene/phesgo/logo/PHESGO-US-Logo-RGB-2021.genecoreimg.1200.png)
PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) | A Treatment for HER2-Positive Breast Cancer
![Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates - Merck .com Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates - Merck .com](https://s2.q4cdn.com/584635680/files/doc_multimedia/merck_logo.jpg)
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates - Merck .com
![Long-Acting Injectable Suspensions | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Long-Acting Injectable Suspensions | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](https://media.americanpharmaceuticalreview.com/m/28/article/587062-1.jpg)
Long-Acting Injectable Suspensions | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
![Long-Acting Injectable Suspensions | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Long-Acting Injectable Suspensions | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](https://media.americanpharmaceuticalreview.com/m/28/article/587062-2.jpg)